A single-arm IIT study of HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-Line treatment in gastrointestinal cancer with liver ...

Mutational profiling of appendiceal tumors from diagnostic specimens and circulating tumor DNA. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

Leaders, innovators and change makers from a breadth of disciplines are being recognized at McMaster’s spring convocation ceremonies for their tremendous accomplishments and contributions to . . .

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management ...

Candel Therapeutics essentially uses a dual-virus strategy with CAN-2409 and CAN-3110 immunotherapies. Find out why CADL ...

Under the agreement, the company's oncolytic virus candidates ELC-100 and ELC-201 will be included in tests aimed at developing a new type of companion diagnostic to predict the potential success ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.

A study appearing in Nature investigated the role of astrocytes, an abundant cell type in the brain, in regulating an immune ...

Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers.

Latest News of Japan Japan is rapidly advancing its role in the global immunotherapy market through both policy and ...

Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced that it will showcase its latest research ...